Biotech | May 11, 2022
New nirsevimab data analyses reinforce efficacy against RSV
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
The campaign will be available in nine Indian languages namely Hindi, English, Odia, Marathi, Tamil, Telugu, Kannada, Malayalam and Bengali
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
Under the 5-year exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
Subscribe To Our Newsletter & Stay Updated
